Spots Global Cancer Trial Database for waldenstrom macroglobulinemia
Every month we try and update this database with for waldenstrom macroglobulinemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Rifaximin in Patients With Monoclonal Gammopathy | NCT03820817 | IgA Monoclonal ... IgG Monoclonal ... IgM Monoclonal ... Light Chain Dep... Monoclonal Gamm... Smoldering Wald... Waldenstrom Mac... Gammopathy, Mon... Gammopathy Igg | Rifaximin | 18 Years - | Emory University | |
| APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia | NCT04260217 | Waldenstrom Mac... | APG2575 400 mg APG2575 600 mg APG2575 800 mg | 18 Years - 95 Years | Ascentage Pharma Group Inc. | |
| Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia | NCT00777738 | Waldenstrom Mac... | BORTEZOMIB | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer | NCT00546377 | Leukemia Lymphoma | filgrastim pegfilgrastim rituximab sargramostim cyclophosphamid... mitoxantrone hy... pentostatin fluorescence in... gene rearrangem... polymerase chai... protein express... flow cytometry biopsy | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease | NCT00176475 | Leukemia Lymphoma Multiple Myelom... | rituximab therapeutic all... | 18 Years - | Rutgers, The State University of New Jersey | |
| Bone Marrow Transplantation in Treating Patients With Lymphoma | NCT00002829 | Lymphoma | Recombinant Int... Cyclophosphamid... Etoposide Mesna Bone Marrow Tra... Radiation Thera... | 15 Years - 60 Years | M.D. Anderson Cancer Center | |
| Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma | NCT00980395 | Lymphoma Mantle Cell Lym... Indolent Lympho... SLL | rituximab bortezomib cladribine | 18 Years - | University of Arizona | |
| BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I) | NCT04018248 | Diffuse Large B... Follicular Lymp... Chronic Lymphoc... Small Lymphocyt... B Cell Lymphoma Marginal Zone L... Waldenstrom Mac... Peripheral T Ce... | BR101801 (Phase... BR101801 (Phase... | 18 Years - | Boryung Pharmaceutical Co., Ltd | |
| Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma | NCT00397800 | Lymphoma | rituximab cyclophosphamid... fludarabine pho... yttrium Y 90 ib... | 50 Years - 75 Years | Technical University of Munich | |
| Prognostic Value of Circulating Tumoral DNA After the First 6 Months of Treatment in Patients With Waldenström Macroglobulinemia | NCT04893564 | Waldenstrom's D... Waldenstrom Mac... | bone marrow sam... blood sample | 18 Years - | Centre Hospitalier Universitaire, Amiens | |
| Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia | NCT00004889 | Lymphoma | rituximab | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas | NCT01732926 | Indolent Non-Ho... | Idelalisib Rituximab Bendamustine Placebo | 18 Years - | Gilead Sciences | |
| Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma | NCT00278161 | Leukemia Lymphoma | Pegfilgrastim Rituximab Cyclophosphamid... | 18 Years - 70 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy | NCT00891137 | Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic... | human myeloid p... | 12 Years - 65 Years | Cellerant Therapeutics | |
| Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma | NCT00004192 | Lymphoma Neutropenia | filgrastim pegfilgrastim cisplatin cytarabine etoposide methylprednisol... | 18 Years - 120 Years | University of Nebraska | |
| Rifaximin in Patients With Monoclonal Gammopathy | NCT03820817 | IgA Monoclonal ... IgG Monoclonal ... IgM Monoclonal ... Light Chain Dep... Monoclonal Gamm... Smoldering Wald... Waldenstrom Mac... Gammopathy, Mon... Gammopathy Igg | Rifaximin | 18 Years - | Emory University | |
| Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas | NCT01732913 | Indolent Non-Ho... | Placebo Rituximab Idelalisib | 18 Years - | Gilead Sciences | |
| Study of VTD in Waldenstrom's Macroglobulinemia | NCT03335098 | Waldenstrom Mac... Lymphoplasmacyt... | Bortezomib | 19 Years - | Seoul National University Hospital | |
| Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer | NCT00039676 | Waldenstrom Mac... Chronic Lymphoc... Hodgkin Disease NonHodgkin Lymp... Mixed Lymphopro... | 11 Months - | National Institutes of Health Clinical Center (CC) | ||
| Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies | NCT01947140 | Lymphoid Malign... Multiple Myelom... Lymphoma Hodgkin Lymphom... Non-hodgkin Lym... | Pralatrexate Romidepsin | 18 Years - | Columbia University | |
| Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia | NCT03630042 | Waldenstrom Mac... | Pembrolizumab Rituximab | 18 Years - | University College, London | |
| Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma | NCT00784927 | Lymphoma | rituximab cyclophosphamid... dexamethasone lenalidomide | 18 Years - 120 Years | Mayo Clinic | |
| Prognostic Value of Circulating Tumoral DNA After the First 6 Months of Treatment in Patients With Waldenström Macroglobulinemia | NCT04893564 | Waldenstrom's D... Waldenstrom Mac... | bone marrow sam... blood sample | 18 Years - | Centre Hospitalier Universitaire, Amiens | |
| ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies | NCT04043845 | Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Marginal Zone L... | Ibrutinib LY3214996 | 18 Years - | Dana-Farber Cancer Institute | |
| Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant | NCT01251575 | Adult Acute Lym... Adult Acute Mye... Adult Diffuse L... Adult Myelodysp... Adult Non-Hodgk... Aggressive Non-... Childhood Acute... Childhood Acute... Childhood Diffu... Childhood Myelo... Childhood Non-H... Chronic Lymphoc... Chronic Lymphoc... Chronic Phase C... Hematopoietic a... Mantle Cell Lym... Plasma Cell Mye... Prolymphocytic ... Recurrent Chron... Refractory Chro... T-Cell Prolymph... Waldenstrom Mac... Recurrent Diffu... Recurrent Hodgk... | Allogeneic Hema... Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Peripheral Bloo... Sirolimus Total-Body Irra... | - | Fred Hutchinson Cancer Center | |
| A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | NCT03740529 | Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Marginal Zone L... B-cell Lymphoma Small Lymphocyt... | Pirtobrutinib Venetoclax Rituximab | 18 Years - | Eli Lilly and Company | |
| Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers | NCT00003572 | Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | peripheral bloo... mycophenolate m... tacrolimus allogeneic bone... radiation thera... | 18 Years - 70 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Study to Evaluate the Efficacy and Safety of BGB-11417 in Participants With Waldenström's Macroglobulinemia | NCT05952037 | Waldenstrom Mac... Waldenstrom's M... Waldenstrom's M... | BGB-11417 | 18 Years - | BeiGene | |
| A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | NCT03162536 | Lymphoma, B-Cel... Small Lymphocyt... Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Diffuse Large B... Richter's Trans... Follicular Lymp... Marginal Zone L... | Nemtabrutinib | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies | NCT01947140 | Lymphoid Malign... Multiple Myelom... Lymphoma Hodgkin Lymphom... Non-hodgkin Lym... | Pralatrexate Romidepsin | 18 Years - | Columbia University | |
| Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia | NCT01779167 | Waldenstrom Mac... | Thalidomide Lenalidomide Rituximab | 18 Years - | Weill Medical College of Cornell University | |
| Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma | NCT01045928 | Adult Non-Hodgk... Adult Grade III... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Cutaneous B-cel... Extranodal Marg... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Splenic Margina... Stage I Adult B... Stage I Adult D... Stage I Adult D... Stage I Adult D... Stage I Adult I... Stage I Adult L... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Mantle ... Stage I Margina... Stage I Small L... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Waldenstrom Mac... | lenalidomide rituximab polymerase chai... nucleic acid se... polymorphism an... flow cytometry laboratory biom... | 18 Years - | Case Comprehensive Cancer Center | |
| Chemotherapy and Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma | NCT00002510 | Lymphoma | filgrastim cyclophosphamid... etoposide mesna peripheral bloo... radiation thera... | 16 Years - 65 Years | Temple University | |
| UCN-01 in Treating Patients With Advanced Cancer | NCT00003289 | Leukemia Lymphoma Unspecified Adu... | 7-hydroxystauro... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia | NCT04624906 | Waldenstrom Mac... | Acalabrutinib Bendamustine Rituximab | 18 Years - | Sunnybrook Health Sciences Centre | |
| Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome | NCT02269592 | Monoclonal Gamm... Chronic Lymphoc... Myelodysplastic... Hematological M... B-cell Malignan... Myelodysplastic... IgG Monoclonal ... Smoldering Mult... Waldenstrom Mac... | 18 Years - | Dana-Farber Cancer Institute | ||
| Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma | NCT02339922 | Chronic Lymphoc... Follicular Lymp... Lymphoplasmacyt... Mantle Cell Lym... Marginal Zone L... Recurrent Extra... Refractory Extr... Small Lymphocyt... Waldenstrom Mac... | Ixazomib Citrat... Laboratory Biom... Rituximab | 18 Years - | University of Washington | |
| Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG | NCT02916979 | Leukemia, Lymph... Leukemia, Myelo... Myelodysplastic... Myelofibrosis Lymphoma, Malig... Multiple Myelom... Waldenstrom Mac... | Fludarabine Busulfan Rabbit ATG Methotrexate | 18 Years - 75 Years | Dartmouth-Hitchcock Medical Center | |
| PS-341 in Treating Patients With Advanced Cancer | NCT00006362 | Leukemia Lymphoma Multiple Myelom... Precancerous Co... Unspecified Adu... | bortezomib | 18 Years - | Mayo Clinic | |
| Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant | NCT01251575 | Adult Acute Lym... Adult Acute Mye... Adult Diffuse L... Adult Myelodysp... Adult Non-Hodgk... Aggressive Non-... Childhood Acute... Childhood Acute... Childhood Diffu... Childhood Myelo... Childhood Non-H... Chronic Lymphoc... Chronic Lymphoc... Chronic Phase C... Hematopoietic a... Mantle Cell Lym... Plasma Cell Mye... Prolymphocytic ... Recurrent Chron... Refractory Chro... T-Cell Prolymph... Waldenstrom Mac... Recurrent Diffu... Recurrent Hodgk... | Allogeneic Hema... Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Peripheral Bloo... Sirolimus Total-Body Irra... | - | Fred Hutchinson Cancer Center | |
| Bone Marrow Transplantation in Treating Patients With Lymphoma | NCT00002829 | Lymphoma | Recombinant Int... Cyclophosphamid... Etoposide Mesna Bone Marrow Tra... Radiation Thera... | 15 Years - 60 Years | M.D. Anderson Cancer Center | |
| Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma | NCT04840602 | Lymphoplasmacyt... Waldenstrom Mac... | Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Ibrutinib Positron Emissi... Rituximab Venetoclax | 18 Years - | National Cancer Institute (NCI) | |
| Etoposide in Treating Patients With Relapsed Non-Hodgkin's Lymphoma | NCT00002880 | Lymphoma | Etoposide phosp... | - | Alliance for Clinical Trials in Oncology | |
| Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia | NCT01008462 | B-Cell Prolymph... Hypodiploidy Loss of Chromos... Plasma Cell Leu... Progression of ... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Recurrent Chron... Recurrent Plasm... Recurrent Small... Refractory Chil... Refractory Chro... Refractory Non-... Refractory Plas... Refractory Smal... t(14;16) t(4;14) T-Cell Prolymph... Waldenstrom Mac... | Allogeneic Bone... Allogeneic Hema... Autologous Hema... Autologous-Allo... Carmustine Cyclophosphamid... Cytarabine Etoposide Fludarabine Pho... Laboratory Biom... Melphalan Mycophenolate M... Peripheral Bloo... Tacrolimus Total-Body Irra... | - 75 Years | Fred Hutchinson Cancer Center | |
| A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | NCT03162536 | Lymphoma, B-Cel... Small Lymphocyt... Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Diffuse Large B... Richter's Trans... Follicular Lymp... Marginal Zone L... | Nemtabrutinib | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders | NCT03601819 | Lymphoma, T-Cel... Lymphoma, T-Cel... Chronic Lymphoc... Lymphoprolifera... Waldenstrom Mac... Lymphoplasmacyt... Mantle Cell Lym... | Pacritinib | 18 Years - | University of Michigan Rogel Cancer Center | |
| Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia | NCT02952508 | Waldenstrom Mac... Multiple Myelom... Chronic Lymphoc... Small Lymphocyt... Lymphoplasmacyt... Marginal Zone L... Mantle Cell Lym... Diffuse Large B... Central Nervous... | Iopofosine I 13... Iopofosine I 13... Iopofosine I 13... | 18 Years - | Cellectar Biosciences, Inc. | |
| Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma | NCT00980395 | Lymphoma Mantle Cell Lym... Indolent Lympho... SLL | rituximab bortezomib cladribine | 18 Years - | University of Arizona | |
| Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas | NCT02332980 | Recurrent B-Cel... Recurrent Chron... Recurrent Extra... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Lymph... Recurrent Margi... Recurrent Nodal... Recurrent Small... Recurrent Splen... Recurrent Walde... Refractory B-Ce... Refractory Chro... Refractory Extr... Refractory Foll... Refractory Lymp... Refractory Noda... Refractory Smal... Refractory Sple... Refractory Wald... Richter Syndrom... Waldenstrom Mac... | Ibrutinib Idelalisib Laboratory Biom... Pembrolizumab | 18 Years - | Mayo Clinic | |
| ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy | NCT05065554 | IgM MGUS Waldenstrom Mac... Neuropathy;Peri... | Acalabrutinib Rituximab | 18 Years - | Dana-Farber Cancer Institute | |
| Covid-19 Vaccine Responsiveness in MM and Waldenstrom | NCT04830046 | Multiple Myelom... Waldenstrom Mac... Immune System D... Covid19 | 18 Years - | Massachusetts General Hospital | ||
| Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers | NCT01240525 | Graft Versus Ho... Leukemia Lymphoma Myeloma Myelodysplastic... | CD4 DLI No DLI | 18 Years - 69 Years | University College, London | |
| Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant | NCT01231412 | Acute Lymphobla... Acute Myeloid L... Aggressive Non-... Chronic Lymphoc... Diffuse Large B... Hematopoietic a... Indolent Non-Ho... Mantle Cell Lym... Myelodysplastic... Myeloproliferat... Prolymphocytic ... Recurrent Chron... Recurrent Plasm... Refractory Chro... Refractory Chro... Refractory Hodg... Small Lymphocyt... T-Cell Chronic ... Waldenstrom Mac... | Allogeneic Hema... Cyclosporine Fludarabine Pho... Mycophenolate M... Peripheral Bloo... Sirolimus Total-Body Irra... | - | Fred Hutchinson Cancer Center | |
| Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma | NCT02257242 | Lymphoma, Non-H... Lymphoma, Folli... Lymphoma, Mantl... Lymphoma, Small... Waldenstrom Mac... Lymphoma, B-Cel... | Rituximab Bendamustine Vincristine sul... | 18 Years - | Brown University | |
| Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms | NCT00082784 | Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Refractory Plas... Splenic Margina... Waldenstrom Mac... | Bortezomib Alvocidib Hydro... Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma | NCT03364231 | Marginal Zone L... Waldenstrom Mac... Non Follicular ... | Umbralisib | 18 Years - | TG Therapeutics, Inc. | |
| Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia | NCT01351935 | B Cell Non-Hodg... Chronic Lymphoc... Waldenstrom Mac... | AVL-292 | 18 Years - | Celgene | |
| Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma | NCT00004192 | Lymphoma Neutropenia | filgrastim pegfilgrastim cisplatin cytarabine etoposide methylprednisol... | 18 Years - 120 Years | University of Nebraska | |
| Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Lymphoma or Waldenstrom's Macroglobulinemia | NCT00004107 | Leukemia Lymphoma | filgrastim autologous bone... peripheral bloo... indium In 111 m... yttrium Y 90 ep... | 18 Years - 80 Years | Garden State Cancer Center at the Center for Molecular Medicine and Immunology | |
| ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies | NCT04043845 | Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Marginal Zone L... | Ibrutinib LY3214996 | 18 Years - | Dana-Farber Cancer Institute | |
| Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia | NCT01351935 | B Cell Non-Hodg... Chronic Lymphoc... Waldenstrom Mac... | AVL-292 | 18 Years - | Celgene | |
| Etoposide in Treating Patients With Relapsed Non-Hodgkin's Lymphoma | NCT00002880 | Lymphoma | Etoposide phosp... | - | Alliance for Clinical Trials in Oncology | |
| A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) | NCT03833180 | Chronic Lymphoc... Mantle Cell Lym... Follicular Lymp... Marginal Zone L... Diffuse Large B... Richter Transfo... Burkitt Lymphom... Lymphoplasmacyt... T-cell Non-Hodg... Acute Lymphoid ... Acute Myeloid L... Waldenstrom Mac... | Zilovertamab ve... | 18 Years - | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | |
| Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma | NCT00003605 | Lymphoma | rituximab cyclophosphamid... | - | Hoag Memorial Hospital Presbyterian | |
| Covid-19 Vaccine Responsiveness in MM and Waldenstrom | NCT04830046 | Multiple Myelom... Waldenstrom Mac... Immune System D... Covid19 | 18 Years - | Massachusetts General Hospital | ||
| UCN-01 in Treating Patients With Advanced Cancer | NCT00003289 | Leukemia Lymphoma Unspecified Adu... | 7-hydroxystauro... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Long-Term Effects of Iodine I Tositumomab and Autologous Bone Marrow or Stem Cell Transplantation in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | NCT00098566 | Lymphoma Quality of Life | 18 Years - 120 Years | Fred Hutchinson Cancer Center | ||
| Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia | NCT01118689 | Relapsed Multip... Refractory Mult... Waldenstrom Mac... | MLN0128 | 18 Years - | Millennium Pharmaceuticals, Inc. | |
| AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas | NCT06340737 | Follicular Lymp... Mantle Cell Lym... Hairy Cell Leuk... Lymphoplasmacyt... Burkitt Lymphom... Marginal Zone L... Waldenstrom Mac... | CD22CART Infusi... | 18 Years - | Stanford University | |
| Study of Oral LOXO-338 in Patients With Advanced Blood Cancers | NCT05024045 | Leukemia, Lymph... Lymphoma, B-cel... Lymphoma, Non-H... Multiple Myelom... B-cell Lymphoma Waldenstrom Mac... Lymphoma, Mantl... | LOXO-338 Pirtobrutinib | 18 Years - | Eli Lilly and Company | |
| Ibrutinib + Venetoclax in Untreated WM | NCT04273139 | Waldenstrom Mac... MYD88 Gene Muta... | IBRUTINIB Venetoclax | 18 Years - | Dana-Farber Cancer Institute | |
| A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) | NCT03833180 | Chronic Lymphoc... Mantle Cell Lym... Follicular Lymp... Marginal Zone L... Diffuse Large B... Richter Transfo... Burkitt Lymphom... Lymphoplasmacyt... T-cell Non-Hodg... Acute Lymphoid ... Acute Myeloid L... Waldenstrom Mac... | Zilovertamab ve... | 18 Years - | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | |
| B-Cell Hematologic Malignancy Vaccination Registry | NCT02298816 | Monoclonal Gamm... Multiple Myelom... Waldenstrom Mac... Lymphocytosis Lymphoma, Non-H... B-Cell Chronic ... Hematological M... | - | Aurora Health Care | ||
| Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia | NCT02952508 | Waldenstrom Mac... Multiple Myelom... Chronic Lymphoc... Small Lymphocyt... Lymphoplasmacyt... Marginal Zone L... Mantle Cell Lym... Diffuse Large B... Central Nervous... | Iopofosine I 13... Iopofosine I 13... Iopofosine I 13... | 18 Years - | Cellectar Biosciences, Inc. | |
| Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer | NCT05172700 | Leukemia, Lymph... Lymphoma, Lymph... Lymphoma, Mantl... Waldenstrom Mac... Ritcher's Trans... | Pirtobrutinib | 18 Years - | Eli Lilly and Company | |
| Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia | NCT00003512 | Waldenstrom Mac... | Antineoplaston ... | 18 Years - 99 Years | Burzynski Research Institute | |
| Prognostic Value of Circulating Tumoral DNA After the First 6 Months of Treatment in Patients With Waldenström Macroglobulinemia | NCT04893564 | Waldenstrom's D... Waldenstrom Mac... | bone marrow sam... blood sample | 18 Years - | Centre Hospitalier Universitaire, Amiens | |
| Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia | NCT03620903 | Waldenstrom Mac... | Ibrutinib / Bor... | 18 Years - | University of Ulm | |
| Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia | NCT04263480 | Waldenstrom Mac... | Carfilzomib + I... Ibrutinib | 18 Years - | University of Ulm | |
| Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia | NCT01118689 | Relapsed Multip... Refractory Mult... Waldenstrom Mac... | MLN0128 | 18 Years - | Millennium Pharmaceuticals, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
